Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Haematological malignancies

5353 - Copanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: combined analysis from phase I and II studies

Date

21 Oct 2018

Session

Proffered paper session - Haematological malignancies

Topics

Cytotoxic Therapy

Tumour Site

Lymphomas

Presenters

Martin Dreyling

Citation

Annals of Oncology (2018) 29 (suppl_8): viii359-viii371. 10.1093/annonc/mdy286

Authors

D. Healy1, P.L. Zinzani2, A. Santoro3, L. Mollica4, G.A. Follows5, K. Bouabdallah6, F. Morschhauser7, A. Patnaik8, L. Huang9, F. Hiemeyer10, A. Benson9, I. Genvresse11, J.E. Garcia-Vargas12, B.H. Childs13, M.H. Dreyling14

Author affiliations

  • 1 Medical Affairs, Bayer HealthCare Pharmaceuticals Inc, New York/US
  • 2 Institute Of Hematology 'l.e A. Seragnoli', University of Bologna, 40138 - Bologna/IT
  • 3 Department Of Oncology And Hematology, Istituto Clinico Humanitas, 20089 - Rozzano/IT
  • 4 Department Of Hematology, Hôpital Maisonneuve-Rosemont-Montreal, Montreal/CA
  • 5 Department Of Haematology, Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital, Cambridge/GB
  • 6 Service D'hématologie Et De Thérapie Cellulaire, University Hospital of Bordeaux, Pessac/FR
  • 7 Department Of Hematology, CHRU - Hôpital Claude Huriez, Lille/FR
  • 8 Phase I Medical Oncology Program, South Texas Accelerated Research Therapeutics (START), 78229 - San Antonio/US
  • 9 Clinical Statistics, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 10 Clincial Statistics, Bayer AG, Berlin/DE
  • 11 Pharmaceutical Division, Bayer AG, Berlin/DE
  • 12 Clinical Development, Bayer HealthCare Pharmaceuticals, 07981 - Whippany/US
  • 13 Clinical Development, Bayer HealthCare Pharmaceuticals, New York/US
  • 14 Medizinische Klinik Iii - Klinikum Der Universität, Ludwig Maximilians University Munich, 81377 - Munich/DE
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5353

Background

Copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with potent PI3K-α and PI3K-δ activity, has been explored as monotherapy in four phase I or II studies in patients with relapsed or refractory (r/r) indolent B-cell lymphoma having progressed on two or more prior lines of therapy. Because of similar entry criteria for all four studies, we therefore conducted a combined safety and efficacy analysis.

Methods

Patients with indolent B-cell non-Hodgkin lymphoma and r/r to ≥ 2 prior lines of treatment were eligible. Previous treatment included rituximab and an alkylating agent. Copanlisib was administered intravenously intermittently on days 1, 8 and 15 of a 28-day cycle at either 0.8 mg/kg (studies NCT00962611, NCT02155582, and NCT01660451-A) or as a flat 60 mg dose (NCT01660451-B). The primary efficacy endpoint was objective response rate (ORR) using Cheson criteria based on central independent review and/or investigator assessment.

Results

The full analysis set comprised 168 patients, with follicular (n = 126) and marginal zone (n = 26), being the most common lymphoma sub-types. The median age was 64 (range 25-82), with ECOG status 0/1 being 56%/40%. The most common grade (G) 3/4 treatment emergent adverse events (AEs) were transient hyperglycemia (32%/6%, respectively) and transient hypertension (27%/0, respectively). Other all-grade AEs (all-grade%/G3%/G4%) occurring in > 25% of patients included diarrhea (36/5/0), fatigue (29/3/0), and nausea (26/1/0). Serious AEs of interest included pneumonia (10/7/1), pneumonitis (6/3/0) and one case of colitis (G4). The ORR for the entire dataset was 60%, with 21 (12%) patients with complete responses (CR; 1 uCR), 79 (47%) with partial responses (PR), and 51 (30%) with stable disease (SD). Based on investigator assessments, the ORR was 54%, with 9 (5%) CR, 81 (48%) PR, and 54 (32%) SD.

Conclusions

Treatment of indolent B-cell lymphoma patients with copanlisib administered intermittently and intravenously resulted in a manageable and predictable safety profile, with a low incidence of severe GI-related toxicities. The ORR for indolent lymphoma patients treated with copanlisib was robust by both independent and investigator analysis.

Clinical trial identification

NCT00962611, NCT02155582, NCT01660451.

Legal entity responsible for the study

Bayer AG.

Funding

Bayer AG.

Editorial Acknowledgement

Disclosure

A. Santoro: Advisory board: Bayer, Roche, Novartis, BMS, MSD, Lilly, AstraZeneca, Servier. L. Huang, F. Hiemeyer, A. Benson, I. Genvresse, J.E. Garcia-Vargas, B.H. Childs: Employee: Bayer. M.H. Dreyling: Research funding: Bayer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.